CompScripts

PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer

With 9 new poly adenosine diphosphate-ribose polymerase (PARP) inhibitor drugs approved for ovarian cancer over the past 6 years, increasing amounts of data are finding that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

https://ryze.ly/c181abe5

PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

What Are the Advantages of Social Media for Pharmacy Professionals?

Social media platforms are constantly changing and it is important to keep up with their evolution to optimize usage. Sometimes it is difficult to start. Many individuals only have personal Facebook accounts. What should you post and how often? Should you tweet or retweet? Share an article on LinkedIn or just like a post?

https://ryze.ly/53a3fe10

What Are the Advantages of Social Media for Pharmacy Professionals? As the profession moves more toward the internet, it is helpful to know how to best use the various platforms.

The Pharmacist’s Role in Bleeding Disorders

March is Bleeding Disorders Awareness Month, which gives pharmacists the opportunity to advocate for and honor patients with bleeding disorders. Having a bleeding disorder can put a patient at risk of a hemorrhage and death.

https://ryze.ly/092447d8

The Pharmacist’s Role in Bleeding Disorders Pharmacists are an important part of the care team for patients with bleeding disorders, providing services such as medication counseling and reconciliation.

Implications of Phase 2 Trial Assessing Niraparib in the Treatment of Uterine Serous Carcinoma

Pharmacy Times interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute and associate professor at Zucker School of Medicine in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

https://ryze.ly/cb75eb02

Implications of Phase 2 Trial Assessing Niraparib in the Treatment of Uterine Serous Carcinoma Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors

Although the era of personalized medicine has arrived, there remains much to be discussed regarding platinum sensitive disease among patients with newly diagnosed or recurrent ovarian cancer, explained David O’Malley, MD, during a presentation at the Society of Gynecologic Oncology annual meeting. When looking at some of the market data, only approximately 40% of patients with platinum sensitive disease are receiving a poly (ADP-ribose) polymerase (PARP) inhibitor in the first-line setting.

https://ryze.ly/7d8d3cc6

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.